Skip Navigation

European Heart Journal 1986 7(10):859-865;
Copyright © 1986 by the European Society of Cardiology.
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by BRANAGAN, J. P.
Right arrow Articles by WALSH, M. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by BRANAGAN, J. P.
Right arrow Articles by WALSH, M. J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1986 The European Society of Cardiology

Effect of early treatment with nifedipine in suspected acute myocardial infarction

J. P. BRANAGAN, K. WALSH*,, P. KELLY{dagger}, W. C. COLLINS{ddagger}, D. MCCAFFERTY and M. J. WALSH

Department of Cardiology, St James's Hospital Dublin 8, Ireland

revised 7 April 1986; accepted 5 February 1986.

Address for correspondence: M. J. Walsh, Department of Cardiology, St James's Hospital, Dublin 8, Ireland.

Abstract

In this single centre prospective, double blind study, 98 patients with suspected acute myocardial infarction (AMI) were randomized, within six hours, to nifedipine 10 mg (46 patients) or placebo (52 patients) both administered sublingually. The delay time from onset of chest pain to treatment was 3.33±0.2 hours (mean±SEM) and 3.28±0.18 hours for the nifedipine and placebo treated groups, respectively. Treatment was continued orally for 3 days. AMI was confirmed in 28 patients given nifedipine and 23 patients given placebo. Infarct sizing by CK-MB isoenzyme release was possible, for technical reasons, in only 23 patients nifedipine and 17 patients on placebo. CK-M B isoenzyme release was 710±104IUI–1 and 655±118IUI–1 for the nifedipine and placebo treated groups respectively (P>0.05). In the acute coronary insufficiency (ACI) group—18 patients given nifedipine and 29 patients given placebo—there was no significant difference in duration of admission, urgent cardiac readmission or progression to AMI within one month. Study withdrawal occurred in 15.3%—8 nifedipine and 7 placebo. Overall, one month mortality was 10.2% with 5 deaths in both the nifedipine and placebo treated groups. Early treatment with nifedipine did not reduce enzymatically determined infarct size or one month mortality in patients with AMI, or reduce one month morbidity or mortality in patients with ACI.

Key Words: Nifedipine • MB-CK myocardial infarct sizing • one month mortality • ischaemic heart disease


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Arch Intern MedHome page
J. R. Kizer and S. E. Kimmel
Epidemiologic Review of the Calcium Channel Blocker Drugs: An Up-to-date Perspective on the Proposed Hazards
Arch Intern Med, May 14, 2001; 161(9): 1145 - 1158.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
P. Theroux, J. Gregoire, C. Chin, G. Pelletier, P. de Guise, and M. Juneau
Intravenous diltiazem in acute myocardial infarction: Diltiazem as adjunctive therapy to activase (DATA) trial
J. Am. Coll. Cardiol., September 1, 1998; 32(3): 620 - 628.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
C. D. Furberg, B. M. Psaty, and J. V. Meyer
Nifedipine : Dose-Related Increase in Mortality in Patients With Coronary Heart Disease
Circulation, September 1, 1995; 92(5): 1326 - 1331.
[Abstract] [Full Text]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.